Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial

• Verfasst von: Witzens-Harig, Mathias [VerfasserIn]
• Verfasst von: Hensel, Manfred [VerfasserIn]
• Verfasst von: Unterhalt, Michael [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Titel: Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial
• Verf.angabe: Mathias Witzens-Harig, Manfred Hensel, Michael Unterhalt, Klaus Herfarth
• E-Jahr: 2011
• Jahr: 26 February 2011
• Umfang: 6 S.
• Fussnoten: Gesehen am 21.11.2022
• Titel Quelle: Enthalten in: BMC cancer
• Ort Quelle: London : BioMed Central, 2001
• Jahr Quelle: 2011
• Band/Heft Quelle: 11(2011), Artikel-ID 87, Seite 1-6
• ISSN Quelle: 1471-2407
• DOI: doi:10.1186/1471-2407-11-87
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Complete Remission Rate
• Sach-SW: Follicular Lymphoma
• Sach-SW: Mantle Cell Lymphoma
• Sach-SW: Overall Response Rate
• Sach-SW: Relapse Free Survival
• K10plus-PPN: 1823019676

Abstract

The optimal treatment of early stage follicular Lymphoma is a matter of debate. Radiation therapy has frequently been applied with a curative approach beside watchful waiting. Involved field, extended field and total nodal radiation techniques are used in various protocols, but the optimal radiation field still has to be defined. Follicular lymphoma is characterized by stable expression of the CD20 antigen on the tumour cells surface. The anti CD20 antibody Rituximab (Mabthera®) has shown to be effective in systemic therapy of FL in primary treatment, relapse and maintenance therapy.